Jonathan Poh

Jonathan Poh serves as the Chief Technology Officer and has co-authored multiple publications on cancer detection and liquid biopsy technologies. His research has been published in prestigious journals such as Annals of Oncology, Journal of Clinical Oncology, and the American Association for Cancer Research. Poh has expertise in plasma cell-free RNA (cfRNA) sequencing for lung cancer detection and has been involved in developing and evaluating multi-cancer screening tests for cancers prevalent in Asia. Additionally, he has participated in research on mutation concordance between peripheral blood and bone marrow using amplicon-based NGS and has contributed to studies combining liquid biopsy with PET/CT for lung cancer diagnosis.